Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)

SHE:300639 Revenue

Guangdong Hybribio Biotech had revenue of 157.82M CNY in the quarter ending September 30, 2026, a decrease of -7.64%. This brings the company's total for the last twelve months to 641.66M, down -7.16% year-over-year. In the year 2025, Guangdong Hybribio Biotech had annual revenue of 669.64M, down -17.89%. That makes Guangdong Hybribio Biotech the 22,957th largest company in the world by revenue and 4,170th in China.

• Revenue (ttm): 641.66M
• Revenue Growth: -7.16%
• P/S Ratio: 5.60
• Revenue / Employee: 322.44K
• Employees: 1,990
• Market Cap: 3.62B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• in Vitro Diagnostic Reagents, Supporting Instruments and Consumables 549.60M 65.1%
• Medical Testing Services 267.26M 31.7%
• Medical Services 27.49M 3.3%

By Geography

Chart

• China 641.11M 95.7%
• Overseas 28.53M 4.3%

Fiscal year ended Dec 31, 2025 See the full SHE:300639 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	669.64M	-145.89M	-17.89%
Dec 31, 2024	815.53M	-288.93M	-26.16%
Dec 31, 2023	1.10B	-4.49B	-80.27%
Jan 1, 2023	5.60B	2.92B	109.39%
Jan 1, 2022	2.67B	1.32B	97.34%

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error